We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

89 hedge funds and large institutions have $277M invested in UroGen Pharma in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 36 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

31% more call options, than puts

Call options by funds: $2.17M | Put options by funds: $1.65M

10% more funds holding

Funds holding: 81 → 89 (+8)

6% more capital invested

Capital invested by funds: $261M → $277M (+$15.7M)

1.66% less ownership

Funds ownership: 65.87% → 64.21% (-1.7%)

39% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 36

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
89
Holders Change
+8
Holders Change %
+9.88%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
22
Reduced
36
Closed
2
Calls
$2.17M
Puts
$1.65M
Net Calls
+$512K
Net Calls Change
+$3.42M

Top Buyers

Rank Fund Capital Flow
1
ZCA
Zeke Capital Advisors
Pennsylvania
+$11M
2
HCM
Horton Capital Management
Pennsylvania
+$4.86M
3
AIM
ARK Investment Management
Florida
+$4.63M
4
RHJA
Rice Hall James & Associates
California
+$3.92M
5
BlackRock
BlackRock
New York
+$3M

Top Sellers

Rank Fund Capital Flow
1
WCM
Wildcat Capital Management
New York
-$15.3M
2
PF
Phoenix Financial
Israel
-$4.27M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.95M
4
VOYA Investment Management
VOYA Investment Management
Georgia
-$3.85M
5
N
Nuveen
North Carolina
-$2.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$950K -$3.02K -142 -0.3%
Fidelity Investments
27
Fidelity Investments
Massachusetts
$927K – – –
Swiss National Bank
28
Swiss National Bank
Switzerland
$828K – – –
AS
29
Altshuler Shaham
Israel
$828K +$403K +19,000 +81%
Charles Schwab
30
Charles Schwab
California
$796K -$3.88K -183 -0.4%
California Public Employees Retirement System
31
California Public Employees Retirement System
California
$768K – – –
Citadel Advisors
32
Citadel Advisors
Florida
$739K +$34.4K +1,619 +4%
EMG
33
ETF Managers Group
New Jersey
$735K +$151K +7,089 +22%
CBA
34
Coastal Bridge Advisors
Connecticut
$721K – – –
SAM
35
Shikiar Asset Management
New York
$689K -$97.7K -4,600 -12%
Russell Investments Group
36
Russell Investments Group
United Kingdom
$660K -$494K -23,268 -41%
Bank of America
37
Bank of America
North Carolina
$650K -$18.3K -864 -3%
BRA
38
Bender Robert & Associates
California
$606K +$661K +31,131 New
APP
39
Alpha Paradigm Partners
Illinois
$604K +$659K +31,028 New
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$593K +$18.2K +858 +3%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$518K -$43.9K -2,070 -7%
PAI
42
Palo Alto Investors
California
$477K – – –
GCP
43
GSA Capital Partners
United Kingdom
$459K +$500K +23,544 New
UBS AM
44
UBS AM
Illinois
$436K – – –
AllianceBernstein
45
AllianceBernstein
Tennessee
$427K – – –
KHLMTHM
46
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet
Israel
$425K – – –
Barclays
47
Barclays
United Kingdom
$392K +$201K +9,490 +90%
Two Sigma Investments
48
Two Sigma Investments
New York
$386K +$420K +19,800 New
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$368K -$21.2K -1,000 -5%
PPA
50
Parametric Portfolio Associates
Washington
$286K -$300K -14,129 -49%
1
2
3 4

URGN Hedge Fund Activity: Q1 2021 in Review

89 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2021, worth a combined $277M — up 6% from $261M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new URGN positions and 2 closed out — a net gain of 9 holders — while 22 added to existing stakes and 36 trimmed.

The largest buyer was Zeke Capital Advisors, opening a new position worth an estimated $11M. The largest seller was Wildcat Capital Management, cutting an estimated $15.3M.

  • 89 institutional investors held UroGen Pharma (URGN) as of Q1 2021, up from 81 in Q4 2020.
  • Funds reported $277M of UroGen Pharma stock for Q1 2021, up 6% quarter-over-quarter.
  • 11 funds opened new UroGen Pharma positions in Q1 2021 and 2 closed out, a net change of +9 holders.
  • The largest UroGen Pharma buyer in Q1 2021 was Zeke Capital Advisors, an estimated $11M added.
  • The largest UroGen Pharma seller in Q1 2021 was Wildcat Capital Management, an estimated $15.3M sold.

Based on aggregated 13F filings for Q1 2021.